Intra, Johnson & Johnson

Johnson & Johnson Eyes $10 Billion Biopharma Deal with Intra-Cellular Therapies
Johnson Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized
Johnson & Johnson To Buy Intra-Cellular Therapies For $132.00/shr In $14.6 Bln All-cash Deal
Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
(Reuters) -Drug maker Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies, a biopharmaceutical company, Bloomberg News reported on Sunday, citing people familiar with the matter.
Johnson & Johnson Is Exploring Bid for Intra-Cellular Therapies
Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and
Johnson & Johnson exploring takeover of Intra-Cellular - Bloomberg
Johnson & Johnson (JNJ) is evaluating an offer to purchase Intra-Cellular Therapies (NASDAQ:ITCI). Deliberations are on going, and it's not a certainty that JNJ will make an offer for the biotech firm focused on treatments for mental health disorders,
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...
Johnson & Johnson stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
MassDevice4d
Johnson & Johnson MedTech halts Varipulse PFA cases due to stroke reports
Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...
Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...